161 related articles for article (PubMed ID: 37256275)
21. The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study.
Ring HC; Yao Y; Maul JT; Ingram JR; Frew JW; Thorsen J; Nielsen ML; Wu JJ; Thyssen JP; Thomsen SF; Egeberg A
Br J Dermatol; 2022 Oct; 187(4):523-530. PubMed ID: 35603888
[TBL] [Abstract][Full Text] [Related]
22. Real life data on the biopsychosocial effects of Adalimumab in the management of hidradenitis suppurativa: A multicenter cross sectional analysis and consideration of a multisystem monitoring approach to follow up.
Muralidharan V; Pathmarajah P; Peterknecht E; Qazi E; Barlow R; Muralidharan V; Abdullah A; McDonald B; Bewley A
Dermatol Ther; 2021 Jan; 34(1):e14643. PubMed ID: 33296539
[TBL] [Abstract][Full Text] [Related]
23. Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases.
Faivre C; Villani AP; Aubin F; Lipsker D; Bottaro M; Cohen JD; Durupt F; Jeudy G; Sbidian E; Toussirot E; Badot V; Barbarot S; Debarbieux S; Delaporte E; Goegebeur G; Morel J; Nassif A; Duru G; Jullien D;
J Am Acad Dermatol; 2016 Jun; 74(6):1153-9. PubMed ID: 26965410
[TBL] [Abstract][Full Text] [Related]
24. Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa.
Ricceri F; Rosi E; Di Cesare A; Pescitelli L; Fastame MT; Prignano F
Dermatol Ther; 2020 Nov; 33(6):e14387. PubMed ID: 33030281
[TBL] [Abstract][Full Text] [Related]
25. Seven years-experience of adalimumab therapy for Hidradenitis Suppurativa in a real-life dermatologic setting.
Odorici G; Pacetti L; Forconi R; Schettini N; Zedde P; Corazza M; Bettoli V
J Dermatolog Treat; 2022 Jun; 33(4):2063-2067. PubMed ID: 33843413
[TBL] [Abstract][Full Text] [Related]
26. Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs.
Burzi L; Repetto F; Ribero S; Mastorino L; Quaglino P; Dapavo P
Dermatol Ther; 2022 Dec; 35(12):e15866. PubMed ID: 36175129
[TBL] [Abstract][Full Text] [Related]
27. Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review.
Montero-Vilchez T; Pozo-Román T; Sánchez-Velicia L; Vega-Gutiérrez J; Arias-Santiago S; Molina-Leyva A
J Dermatolog Treat; 2022 Feb; 33(1):348-353. PubMed ID: 32279593
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Glatt S; Jemec GBE; Forman S; Sayed C; Schmieder G; Weisman J; Rolleri R; Seegobin S; Baeten D; Ionescu L; Zouboulis CC; Shaw S
JAMA Dermatol; 2021 Nov; 157(11):1279-1288. PubMed ID: 34406364
[TBL] [Abstract][Full Text] [Related]
29. The role of biologic treatment in special scenarios in hidradenitis suppurativa: Facial and nape phenotype, dissecting cellulitis of the scalp, and lymphedema.
Sanchez-Diaz M; Martinez-Lopez A; Salvador-Rodriguez L; Montero-Vilchez T; Arias-Santiago S; Molina-Leyva A
Dermatol Ther; 2021 Mar; 34(2):e14829. PubMed ID: 33527618
[TBL] [Abstract][Full Text] [Related]
30. A case paradoxical hidradenitis suppurativa with janus kinase inhibitor, literature review and pooled analysis of biological agent-induced HS.
Shaharir SS; Jamil A; Chua SH; Arumugam M; Rosli N
Dermatol Ther; 2020 Nov; 33(6):e14021. PubMed ID: 32677247
[TBL] [Abstract][Full Text] [Related]
31. Disease Burden and Treatment Patterns Among US Patients with Hidradenitis Suppurativa: A Retrospective Cohort Study.
Garg A; Geissbühler Y; Houchen E; Choudhary N; Arora D; Vellanki V; Srivastava A; Priyanka ; Darcy J; Richardson C; Kimball AB
Am J Clin Dermatol; 2023 Nov; 24(6):977-990. PubMed ID: 37378875
[TBL] [Abstract][Full Text] [Related]
32. Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System.
Kokolakis G; Wolk K; Schneider-Burrus S; Kalus S; Barbus S; Gomis-Kleindienst S; Sabat R
Dermatology; 2020; 236(5):421-430. PubMed ID: 32610312
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic delay in Hidradenitis suppurativa investigated using data from social media and from statutory health insurances.
Kirschner U; Kahn M; Papukchieva S; Stosio K; Keis A; Biermann MHC; Häusser-Fruh G; Sturm L; Eberl M; Friedrich B; Kurzen H
J Dtsch Dermatol Ges; 2024 Jun; 22(6):803-809. PubMed ID: 38769083
[TBL] [Abstract][Full Text] [Related]
34. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa.
Molinelli E; Sapigni C; Campanati A; Brisigotti V; Offidani A
Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1019-1037. PubMed ID: 32896186
[TBL] [Abstract][Full Text] [Related]
35. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa.
Tzanetakou V; Stergianou D; Giamarellos-Bourboulis EJ
Expert Opin Drug Saf; 2020 Apr; 19(4):381-393. PubMed ID: 32098513
[No Abstract] [Full Text] [Related]
36. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group.
Zouboulis CC; Bechara FG; Dickinson-Blok JL; Gulliver W; Horváth B; Hughes R; Kimball AB; Kirby B; Martorell A; Podda M; Prens EP; Ring HC; Tzellos T; van der Zee HH; van Straalen KR; Vossen ARJV; Jemec GBE
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):19-31. PubMed ID: 30176066
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild-to-moderate hidradenitis suppurativa: A retrospective study.
Molinelli E; Brisigotti V; Simonetti O; Sapigni C; D'Agostino GM; Rizzetto G; Giacchetti A; Offidani A
Dermatol Ther; 2022 Jun; 35(6):e15439. PubMed ID: 35278025
[TBL] [Abstract][Full Text] [Related]
38. Emerging drugs for the treatment of hidradenitis suppurativa.
Folkes AS; Hawatmeh FZ; Wong A; Kerdel FA
Expert Opin Emerg Drugs; 2020 Sep; 25(3):201-211. PubMed ID: 32667213
[TBL] [Abstract][Full Text] [Related]
39. Biologic therapies for the treatment of hidradenitis suppurativa.
Rosales Santillan M; Morss PC; Porter ML; Kimball AB
Expert Opin Biol Ther; 2020 Jun; 20(6):621-633. PubMed ID: 32077334
[No Abstract] [Full Text] [Related]
40. Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis.
Salvador-Rodriguez L; Montero-Vílchez T; Arias-Santiago S; Molina-Leyva A
Dermatology; 2020; 236(4):307-313. PubMed ID: 32135533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
